Fust Matthew K
- SEC CIK
- 0001397266
In the past year, 1 open-market sale filing worth $716.0K and no purchases.
Current role at each company
- CRNX Crinetics Pharmaceuticals, Inc.Directoras of Sep 1, 2026
- ATRA Atara Biotherapeutics, Inc.Directoras of Jun 11, 2026
- NMRA Neumora Therapeutics, Inc.Directoras of May 29, 2026
- RARE Ultragenyx Pharmaceutical Inc.Directoras of May 18, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $716.0K
- 1 filing
- Net
- −$716.0K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Fust Matthew K as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CRNX Crinetics Pharmaceuticals, Inc.
Director8 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 (view filing) | Sep 26 | 4 days | Fust Matthew KDirector | SSale | −16.0K | $44.75 | −$716.0K | −41.2%22.8K after | 10b5-1 |
| Mar 22, 2024 (view filing) | Mar 20 | 2 days | Fust Matthew KDirector | SSale | −60.0K | $44.14 | −$2.65M | −76.4%18.5K after | 4 lots10b5-1 |
| Jul 15, 2022 (view filing) | Jul 13 | 2 days | Fust Matthew KDirector | SSale | −5.70K | $20.96 | −$119.5K | −31.3%12.5K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Fust Matthew KDirector | SSale | −8.95K | $25.50 | −$228.3K | −41.7%12.5K after | |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Fust Matthew KDirector | SSale | −6.05K | $25.50 | −$154.2K | −32.5%12.5K after | |
| Jul 27, 2021 (view filing) | Jul 26 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $19.59 | −$98.0K | −28.5%12.5K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $19.50 | −$97.5K | −28.5%12.5K after | |
| Jul 13, 2021 (view filing) | Jul 12 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $20.71 | −$103.5K | −28.5%12.5K after |
NMRA Neumora Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 18, 2024 (view filing) | Oct 17-18 | 1 day | Fust Matthew KDirector | SSale | −21.8K | $17.02 | −$370.9K | −52.0%20.1K after | 2 lots10b5-1 |
RARE Ultragenyx Pharmaceutical Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Fust Matthew KDirector | SSale | −12.2K | $50.88 | −$620.4K | −45.1%14.9K after | 3 lots10b5-1 |
ATRA Atara Biotherapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2021 (view filing) | Nov 4 | 1 day | Fust Matthew KDirector | SSale | −13.4K | $19.50 | −$260.4K | −29.8%31.5K after |